Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.53 |
| ▸ | CDK2 | P24941 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 7/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL623371 | 1.00 | GAA (0.53) | GAACDK2MEN1KMT2APTGS2 | |
| SCHEMBL623370 | 1.00 | GAA (0.53) | GAACDK2MEN1KMT2APTGS2 | |
| SCHEMBL15315387 | 0.90 | KMT2A (0.50) | GAACDK2MEN1KMT2APTGS2 | |
| SCHEMBL18688530 | 0.89 | KMT2A (0.49) | GAACDK2MEN1KMT2APTGS2 | |
| SCHEMBL13479601 | 0.86 | MAPT (0.47) | GAACDK2MEN1KMT2AMAPT | |
| SCHEMBL22624828 | 0.84 | CDK2 (0.56) | CDK2MEN1KMT2APTGS2MAPT | |
| SCHEMBL10118539 | 0.81 | MEN1 (0.60) | CDK2MEN1KMT2APTGS2MAPT | |
| SCHEMBL15312914 | 0.81 | MEN1 (0.60) | CDK2MEN1KMT2APTGS2MAPT | |
| SCHEMBL15317953 | 0.80 | MAPT (0.54) | GAAMEN1KMT2APTGS2MAPT | |
| SCHEMBL623631 | 0.79 | GAA (0.63) | GAACDK2MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4215614-A1 | COMBINATION THERAPY FOR DYSTROPHIN-RELATED DISEASES | Dynacure (FR) | 2023-07-26 | — | — | EP | claimed |
| US-20260132180-A1 | ONCOSELECTIVE THERAPY | KERNAL BIOLOGICS, INC. | 2026-05-14 | — | — | US | disclosed |
| EP-4709864-A1 | ONCOSELECTIVE THERAPY | Kernal Biologics, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4634662-A1 | POTENCY ASSAY FOR PHARMACEUTICAL PRODUCTS | Repairon Muscle UG (haftungsbeschränkt) (DE) | 2025-10-22 | — | — | EP | disclosed |
| WO-2024255817-A1 | SYSTEMS AND METHOD OF INHIBITING NONSENSE-MEDIATED DECAY WITH CIRCULAR RNAS | PEKING UNIVERSITY (CN) | 2024-12-19 | — | — | WO | disclosed |
| WO-2024233835-A1 | ONCOSELECTIVE THERAPY | KERNAL BIOLOGICS, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| CN-118922359-A | Sorting system and sorting method | 株式会社大福 | 2024-11-08 | — | — | CN | disclosed |
| US-20240358797-A1 | ONCOSELECTIVE CANCER THERAPY | KERNAL BIOLOGICS, INC. | 2024-10-31 | — | — | US | disclosed |
| EP-4429645-A1 | ONCOSELECTIVE CANCER THERAPY | Kernal Biologics, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| WO-2024176694-A1 | SORTING SYSTEM AND SORTING METHOD | 株式会社ダイフク | 2024-08-29 | — | — | WO | disclosed |
| WO-2023149370-A1 | CONTROL SYSTEM, CONTROL METHOD, AND STORAGE MEDIUM | キヤノン株式会社 | 2023-08-10 | — | — | WO | disclosed |
| EP-4215614-A1 | COMBINATION THERAPY FOR DYSTROPHIN-RELATED DISEASES | Dynacure (FR) | 2023-07-26 | — | — | EP | disclosed |
| WO-2023081885-A1 | ONCOSELECTIVE CANCER THERAPY | KERNAL BIOLOGICS, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| EP-3647957-B1 | SUBSTRATE-RELATED OPERATION MACHINE CONTROL DEVICE | FUJI CORP (JP) | 2022-10-19 | — | — | EP | disclosed |
| WO-2022200857-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | MONTE ROSA THERAPEUTICS AG (CH) | 2022-09-29 | — | — | WO | disclosed |
| CN-114729353-A | Expression of engineered tumor-selective proteins | 科纳勒生物公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-111447028-B | Time synchronization method and device | 新华三信息安全技术有限公司 | 2022-05-24 | — | — | CN | disclosed |
| EP-3987028-A1 | ENGINEERED ONCOSELECTIVE PROTEIN EXPRESSION | Kernal Biologics, Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| CN-114114887-A | Control device and control method for electronic device, timepiece body, and band | 卡西欧计算机株式会社 | 2022-03-01 | — | — | CN | disclosed |
| CN-109150955-B | Communication apparatus, communication method, and recording medium | 卡西欧计算机株式会社 | 2022-01-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132180-A1 | ONCOSELECTIVE THERAPY | TRMT1L, NTPCR, DCTD | GAA 3040/4885CDK2 3994/4885MEN1 1665/4885 |
| US-20240358797-A1 | ONCOSELECTIVE CANCER THERAPY | CD274, PDCD1LG2, PDCD1 | GAA 931/4885CDK2 3524/4885MEN1 2450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.